IE922176A1 - Phospholipid composition - Google Patents
Phospholipid compositionInfo
- Publication number
- IE922176A1 IE922176A1 IE217692A IE922176A IE922176A1 IE 922176 A1 IE922176 A1 IE 922176A1 IE 217692 A IE217692 A IE 217692A IE 922176 A IE922176 A IE 922176A IE 922176 A1 IE922176 A1 IE 922176A1
- Authority
- IE
- Ireland
- Prior art keywords
- composition
- phospholipid
- phospholipid composition
- phosphatidylcholine
- process according
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23J—PROTEIN COMPOSITIONS FOR FOODSTUFFS; WORKING-UP PROTEINS FOR FOODSTUFFS; PHOSPHATIDE COMPOSITIONS FOR FOODSTUFFS
- A23J7/00—Phosphatide compositions for foodstuffs, e.g. lecithin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
- A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/0216—Solid or semisolid forms
- A61K8/022—Powders; Compacted Powders
- A61K8/0225—Granulated powders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/55—Phosphorus compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/55—Phosphorus compounds
- A61K8/553—Phospholipids, e.g. lecithin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
- A61K8/731—Cellulose; Quaternized cellulose derivatives
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Birds (AREA)
- Biophysics (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Biochemistry (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Cosmetics (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Packages (AREA)
- Fats And Perfumes (AREA)
Abstract
A powdered or granulated phospholipid compsn. (I) with phosphatidylcholine content at least 80 wt.%, is free from additives. (I) is pref. crystalline, with crystal size 18-0.07mm (6-0.5mm), and with more than 80 (more than 90) wt.% of crystalline phosphatidylcholine components. Esp., it contains 90-96 wt.% of phosphatidylcholine and 0-6% of lysophosphatidylcholine. (I) is prepd. by grinding the phospholipid compsn. with cooling, at below -50 deg.C, opt. after storage at between +5 and -60 deg.C (esp. between 10 and -30 deg.C), partic. for 1-150 (30-70) days. Grinding and/or storage are under an inert gas, esp. N2, CO2 and/or a noble gas. The phospholipid compsn. has been isolated from soya lecithin and contains 90-96 wt.% of phosphatidylcholine. After storage and before grinding, the temp. is brought to room temp. (I) is stored at below 10 (1-6) deg.C, pref. under an inert gas.
Description
This invention relates to a phospholipid composition with the characteristics of the main definition of claim 1 and to a process for the manufacture of such a phospholipid compos20 ition.
Phospholipids occur in both animal and vegetable matter and have to be isolated from these. The main sources are eggs, soybeans, oil seeds and oil fruit, such as coconut copra, palm kernels, groundnuts, rape, sunflower seeds, oil palms and olives.
Phospholipids are isolated from vegetable products by degumming the corresponding vegetable oil with, for example, a small quantity of steam or water. The phospholipid composition produced, also known as lecithin sludge, generally contains ca. 8 to 59% by weight phospholipids and is dried by various methods to yield crude lecithin on drying.
Depending on the initial lecithin sludge used in each case this crude lecithin will have a different chemical composition. Thus according to Weber E.J.; J.A. O.C.S. 58 898 (1981) the most important crude lecithin, soy (soybean) lecithin, is composed, after drying, of ca.: Triglycerides 34.2% phosphatidylcholine 19.1% Diglycerides 0.4% lysophosphatidylcholine 0.7% Free fatty acids 0.4% phosphatidylethanolamine 8.6% 10 Other neutral lipids 0.8% phosphatidylinositol 8.8% Glycolipids 6.5% phosphatidic acid 4.2% Carbohydrate 6.7% N-acy1phosphatidy1- ethanolamine 1.0% 15 others 8.6% Neutral lipids, such as, for example, triglycerides, diglycerides and the like, can be removed from the crude lecithin by deoiling with acetone. The deoiled crude lecithin, also referred to as pure lecithin, is a solid powder capable of being poured, which is available commercially as lecithin granules. The phosphatidylcholine content of pure lecithin lies between ca. 25% by weight and 30% by weight.
The phosphatidylcholine in crude lecithin or pure lecithin can be enriched by known processes. Preferably according to the processes described in European Patents 00 54 770 or 00 54 769. Hereby the crude lecithin is extracted with alcohol. The alcohol-soluble extraction phase is then chromatographed on silicon dioxide at elevated temperatures. On account of its high phosphatidylcholine content the phospholipid composition resulting from the aforesaid process is used for pharmaceutical, cosmetic and dietetic applications. However it exhibits the disadvantage that it is paste-like or waxy depending on its chemical composition. The further processing of this product is often accompanied by considerable problems on account of its consistency which makes it difficult to dose and causes it to stick to the inside walls of vessels, so that the residues remaining in the vessels make frequent and expensive cleaning of the vessels necessary.
In order to eliminate the aforesaid disadvantages in the handling of phospholipid compositions containing large pro10 portions of phosphatidylcholine attempts have already been made to process these products in such a manner that powdered or granule-like high purity lecithins or specific high purity phospholipids are formed.
Thus German Patent 973 741 proposes deoiling crude lecithin with a suitable solvent, for example acetone, separating the deoiled lecithin from the oil extract, then loosening the separated lecithin and drying it as a thin layer. Thereafter the deoiled lecithin can be separated from the layer support used in the form of flocks or leaflets. However it is unlikely that such a process could be carried out nowadays at an economically acceptable cost. Furthermore the phosphatidylcholine content of 30% is too low for the applications described above.
Processes involving the use of additives are also known (US patents 20 57 695 and 30 12 888).
A similar process has been proposed in German patent 38 26 946. Here a special sugar mixture (palatinit) is employed as an additive during the manufacture of the high purity phospholipid composition in order to yield powdered or granulated high purity specific phospholipids or phospholipid compositions .
However the aforesaid known methods possess the disadvantage that additional effort is involved, namely that it is necessary to add and work in an additive. Furthermore the phospholipid compositions prepared by the known methods are only of very restricted application on account of their relatively low phosphatidylcholine concentrations.
The present invention is intended to make available a phospholipid composition and a process for manufacturing such a phospholipid composition, that is particularly simple to carry out and leads to products which are stable on storage.
This intention is fulfilled by a phospholipid composition with the characteristics of patent claim 1 and by a process with the characteristics of patent claim 7.
The phospholipid composition according to the invention with a phosphatidylcholine content of at least 80% by weight takes the form of a powdered or granulated composition and is, hence, free from additives of any sort.
The powdered or granulated phospholipid composition according to the invention exhibits a range of advantages. Thus it is particularly easy to handle on account of its granule25 like or powdered consistency, so that the disadvantages described for the state of the art do not occur. Unexpectedly it was also found that the powdered or granule-like consistency is also maintained when the processing temperature of the powdered or granule-like composition rises to a temperature of about 30 °C. The phospholipid composition also possesses long storage stability of up to several years without any changes occurring in the chemical or physical structure. This is particularly the case if the phospholipid composition is stored at a temperature below 10 °C, preferably at a temperature between 1 °C and 6 °C, preferably under an inert gas.
The aforesaid advantages of the phospholipid composition 5 according to the invention mean that this composition is very readily applied to the manufacture of appropriate finished products, such as, for example, cosmetics, dietetic preparations or pharmaceutical preparations. This is on account of the fact that such powdered or granule-like compositions are particularly simply dosed and can be weighed out with great accuracy and reproducibility, which is not possible in the case of highly viscous or paste-like products. On account of the absence of additives (solidifiers) the composition according to the invention can also be applied where the known phospholipid compositions cannot be used on account of the additives they contain and/or their low phosphatidylcholine content, that is, in particular, for pharmaceutical products.
A particularly suitable embodiment of the composition according to the invention involves the composition according to the invention that, as has already been described, contains at least 80% by weight phosphatidylcholine, being predominantly crystalline. Especially when the composition according to the invention contains more than 80% by weight, and preferably more than 90%, crystalline phosphatidylcholine components, it is found that such a composition particularly possesses the aforesaid advantages that have been described in detail above. In other words such a composition according to the invention contains at least 64% by weight and preferably 72% by weight crystalline phosphatidylcholine components on an absolute basis. Unexpectedly it could be demonstrated that such a composition according to the invention, that preferably was composed primarily of crystalline components, is excellently dispersible in water, which, for example, considerably eases the manufacture of appropriate aqueous suspensions of cosmetic, dietetic or pharmaceutical preparations. The aforesaid ready dispersibility is unknown for phospholipid compositions according to the state of the art which is attributable to the fact that such known compositions are predominantly amorphous in nature.
A further embodiment of the composition according to the 10 invention proposes that this possesses a concentration of at least 90% by weight phosphatidylcholine.
Another embodiment of the aforesaid composition contains the composition according to the invention 93% by wt. ± 3% by wt. phosphatidylcholine and 3% by wt. + 3% by wt. lysophosphatidylcholine, whereby the aforesaid values have been checked by a known 20 quantitative thin-layer chromatographic analysis method.
Such a composition preferably does not contain any phosphatidylethanolamine and/or any phosphatidylinositol.
With respect to the particle size of the phospholipid com25 position according to the invention it may be said that this is adjusted according to the particular field of application. The phospholipid composition is preferably comminuted to a particle or crystallite size between 18 mm and 0.07 mm, particularly to a particle size between 6 mm to 0.5 mm.
The present invention also applies to a process for the preparation of the aforesaid phospholipid compositions.
The process according to the invention for the preparation of the powdered or granulated phospholipid composition starts out with an appropriate phospholipid composition, that, depending on its composition, possesses a pasty to waxy consistency under the usual conditions of storage. In this connection this phospholipid composition is comminuted to the desired powder or granule size while cooled to a temperature below - 50 °C.
Unexpectedly it could be established that phospholipid com10 positions could be comminuted without problems under these temperatures without the need for admixture of the solidifying agents required in the known methods. In addition compositions that have been comminuted in this manner and that contain at least 80% by weight phosphatidylcholine are stable up to a temperature of 30 °C for several months and years so that chemical and physical changes do not occur.
A further specially favoured embodiment of the process according to the invention provides for the storage of the phospholipid composition at temperatures between + 5 °C and - 60 °C, particularly at temperatures between - 10 °C and - 30 °C before comminution. Whereby the storage time varies between one day and 150 days, preferably between 30 days and 70 days depending on the storage temperature chosen. A phospholipid composition stored in the aforesaid manner can be comminuted to the initially mentioned particle size of 18 mm to 0.07 mm, preferably of 6 mm to 0.5 mm within a very short time.
Depending on the particular phospholipid composition employed a further method of execution of the process according to the invention involves the comminution and/or storage of the particular phospholipid composition at the aforesaid temperatures and for the aforesaid storage time under inert gas. In particular the inert gas can be liquid nitrogen, carbon dioxide, a noble gas or a mixture of the aforesaid gases. This method of operation under inert gas prevents an undesired oxidative modification of the phospholipid compos5 ition.
As already described above various highly purified phospholipid compositions isolated from natural products can be employed as starting materials for the process according to the invention, provided that they contain at least 80% by weight phosphatidylcholine. Such a composition can be isolated preferably from eggs, oil seeds and oil fruit and particularly soybean by the known procedures. However, it is particularly suitable when a soy (soybean) lecithin whose phosphatidylcholine content is at least 90% by weight and preferably 93 ± 3% by weight is employed in the process according to the invention. Such a high purity soy lecithin can, for example, be isolated by the methods as they are described in the European patents 0 054 770 and 0 054 769.
In order to be able to store the powdered or granulated product prepared by the process according to the invention over a long period of time without chemical or physical change a further embodiment of the process according to the invention envisages storage at a temperature below 10 °C and preferably between 1 °C and 6 °C.
A further improvement in the storage stability is achieved if the phospholipid composition is sealed into airtight sachets, for example of appropriate aluminium foil, and stored at the aforesaid temperatures.
A further embodiment of the aforesaid process envisages displacing the air contained in the sachets after they have been filled with an inert gas, for example, nitrogen, a noble gas, carbon dioxide or a mixture of the aforesaid gases .
As already described above the powdered or granulated phospholipid composition according to the invention is very easy to handle and can be employed for various purposes. Thus, for example, such a powdered or granulated phospholipid composition can be used as solution promoter, natural sur10 factant and/or liposome former in cosmetic products and especially in pharmaceutical products, since the phospholipid composition according to the invention is free from solidifying agents.
Advantageous further embodiments of the phospholipid composition according to the invention and the process according to the invention are set out in the subsidiary claims.
The process according to the invention is further illus20 trated by the examples that follow.
Example 1 300 kg of a phospholipid composition containing 93% ± 3% by weight phosphatidylcholine that, for example, had been isolated from soybeans according to the processes described in European patents 00 54 770 or 00 54 769 was stored at - 20 °C for 2 months. Immediatley before the phospholipid composition was comminuted it was brought to room tempera30 ture (17 °C to 21 °C). Then the composition was comminuted in a conventional cold milling plant with liquid nitrogen cooling and sealed portionwise in aluminium sachets under inert gase (nitrogen). The product that had been so packed was stored at + 4 °C.
Stability tests revealed that the product retained its powdered or granulated form at temperatures up to + 30 °C.
Immediately before such a product is processed it is warmed 5 to room temperature to avoid the condensation of water onto the comminuted product.
Example 2 jAs described above 100 kg of the aforesaid composition were comminuted in the cold. However in contrast to example 1 th storage time before comminution was one month at -17 °C.
Stability tests revealed that there was no change in consis tency even after storage for 12 weeks at room temperature (20 °C ± 2 °C) after comminution and packing.
The powdered or granulated phospholipid composition so isolated had the following chemical composition: Phosphatidylcholine Phophatidylethanolamine Phosphatidylinositol Lysophosphatidylcholine Water Triglycerides (oils) 94.2% by wt. not detectable not detectable 3.7% by wt. 1.3% by wt. 0.8% by wt.
Example 3 As previously described in example 1, 300 kg phospholipid composition were comminuted together with 150 kg carbon dioxide granules. Whereby the other conditions corresponded to those described in example 1. Π Stability tests revealed that the composition prepared according to example 3, which contained the aforesaid high phosphatidylcholine content, also remained unchanged in consistency even on storage for six months after comminution .
Claims (14)
1. Phospholipid composition with a phosphatidylcholine content of at least 80% by weight wherein the powdered or granulated composition is free from additives. 5
2. Composition according to claim 1 wherein the composition is predominantly crystalline.
3. Composition according to claim 2 wherein the composition contains at least more than 80% by weight, preferably more 10 than 90% by weight crystalline phosphatidylcholine components .
4. Composition according to one of the preceding claims wherein it possesses a phosphatidylcholine content of at 15 least 90%.
5. Composition according to one of the preceding claims wherein it contains 93 ± 3% by wt. phosphatidylcholine and 5 3 ± 3% by wt. lysophosphatidylcholine.
6. Composition according to one of the preceding claims wherein it has a particle or crystallite size between 18 mm and 0.07 mm, preferably between 6 mm and 0.5 mm.
7. A process for the manufacture of the phospholipid composition according to one of claims 1 to 6, wherein the phospholipid composition is comminuted after cooling to a temperature below - 50 °C.
8. A process according to claim 7 wherein the phospholipid composition is stored at temperatures between + 5 °C and - 60 °C, preferably between - 10 °C and - 30 °C before being comminuted .
9. A process according to claim 8 wherein the phospholipid composition is stored for between one day and 150 days, preferably between 30 days and 70 days. 25 10. A process according to one of claims 7 to 9 wherein the comminution and/or the storage of the phospholipid composition is carried out under inert gas. 11. A process according to claim 10 wherein the inert gas is 30 nitrogen, carbon dioxide, a noble gas or a mixture of these gases . Μ 12. A process according to one of claims 7 to 11 wherein a phospholipid composition is chosen that is isolated from soy (soybean) lecithin and contains 93 ± 3% by weight phosphatidylcholine . 13. A process according to claim 8 or 9 wherein the phospholipid composition is returned to room temperature after storage and before comminution.
10. 14. A process according to one of claims 7 to 13 wherein the powdered or granulated phospholipid composition is stored at a temperature lower than 10 °C, preferably at a temperature between 1 °C and 6 °C.
11. 15 15. A process according to claim 14 wherein the powdered or granulated phospholipid composition is stored under inert gas .
12. 16. A phospholipid composition substantially as described herein with reference to the Examples.
13. 17. A process for the manufacture of a phospholipid composition substantially as described herein with reference to the Examples.
14. 18. A phospholipid composition whenever prepared by a process as claimed in any of claims 7 to 15 or 17.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE4122300 | 1991-07-05 | ||
DE4219715A DE4219715C2 (en) | 1991-07-05 | 1992-06-17 | Phospholipidic composition |
Publications (1)
Publication Number | Publication Date |
---|---|
IE922176A1 true IE922176A1 (en) | 1993-01-13 |
Family
ID=25905244
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IE217692A IE922176A1 (en) | 1991-07-05 | 1992-07-03 | Phospholipid composition |
Country Status (8)
Country | Link |
---|---|
EP (1) | EP0521398B1 (en) |
JP (2) | JP3213391B2 (en) |
AT (1) | ATE172600T1 (en) |
CA (1) | CA2073096C (en) |
DE (1) | DE59209542D1 (en) |
DK (1) | DK0521398T3 (en) |
ES (1) | ES2122975T3 (en) |
IE (1) | IE922176A1 (en) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5635206A (en) * | 1994-01-20 | 1997-06-03 | Hoffmann-La Roche Inc. | Process for liposomes or proliposomes |
DE19859455A1 (en) * | 1998-12-22 | 2000-07-06 | Dianorm G Maierhofer Gmbh | Disperse system as a skin care product |
US20030206881A1 (en) * | 2001-05-31 | 2003-11-06 | Peter Fussbroich | Phospholipidic composition as well as the use thereof |
DE10340741A1 (en) * | 2003-09-04 | 2005-03-31 | Degussa Food Ingredients Gmbh | Phospholipid-based formulation |
US8535750B2 (en) | 2005-05-17 | 2013-09-17 | Cargill, Incorporated | Granular lecithins, granular lysolecithins, process for their production and compositions containing them |
EP2387391B1 (en) | 2009-07-24 | 2017-01-11 | MIKA Pharma Gesellschaft für die Entwicklung und Vermarktung pharmazeutischer Produkte mbH | Method for developing a liquid composition to be applied to the skin as a foam and a composition that can be applied topically |
DE102013004199A1 (en) * | 2012-05-15 | 2013-11-21 | Mika Pharma Gesellschaft Für Die Entwicklung Und Vermarktung Pharmazeutischer Produkte Mbh | Pharmaceutical composition |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2948607A1 (en) * | 1979-12-03 | 1981-06-11 | Chemische Fabrik Dr. Meyer-Castens & Co Nfg., 2000 Hamburg | METHOD FOR PRODUCING A LECITHIN-BASED EMULSIFIER |
JPS58164513A (en) * | 1982-03-25 | 1983-09-29 | Teijin Ltd | Active substance on surface of lung and its preparation |
JPS5928456A (en) * | 1982-08-10 | 1984-02-15 | Nichibei Zoki Kk | Nutrient assistant food prepared from brain of food animal |
JPS6310718A (en) * | 1986-07-02 | 1988-01-18 | Tokyo Tanabe Co Ltd | Production of pulmonary surface active substance preparation |
JPH02172994A (en) * | 1988-12-24 | 1990-07-04 | Nippon Oil & Fats Co Ltd | Production of powdered egg yolk lecithin |
-
1992
- 1992-06-26 DK DK92110757T patent/DK0521398T3/en active
- 1992-06-26 AT AT92110757T patent/ATE172600T1/en not_active IP Right Cessation
- 1992-06-26 ES ES92110757T patent/ES2122975T3/en not_active Expired - Lifetime
- 1992-06-26 DE DE59209542T patent/DE59209542D1/en not_active Expired - Fee Related
- 1992-06-26 EP EP92110757A patent/EP0521398B1/en not_active Expired - Lifetime
- 1992-07-03 CA CA002073096A patent/CA2073096C/en not_active Expired - Fee Related
- 1992-07-03 IE IE217692A patent/IE922176A1/en not_active IP Right Cessation
- 1992-07-03 JP JP20036392A patent/JP3213391B2/en not_active Expired - Fee Related
-
2001
- 2001-05-01 JP JP2001134259A patent/JP3500130B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
JP2002037794A (en) | 2002-02-06 |
DE59209542D1 (en) | 1998-12-03 |
JPH05252875A (en) | 1993-10-05 |
CA2073096A1 (en) | 1993-01-06 |
ATE172600T1 (en) | 1998-11-15 |
CA2073096C (en) | 1999-01-19 |
EP0521398A2 (en) | 1993-01-07 |
ES2122975T3 (en) | 1999-01-01 |
EP0521398A3 (en) | 1993-03-31 |
EP0521398B1 (en) | 1998-10-28 |
JP3213391B2 (en) | 2001-10-02 |
DK0521398T3 (en) | 1999-07-05 |
JP3500130B2 (en) | 2004-02-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5310734A (en) | Phospholipid composition | |
US5438044A (en) | Phospholipid composition | |
US4229360A (en) | Process for the dehydration of a colloidal dispersion of lipsomes | |
US4814161A (en) | Drug-containing chlorofluorocarbon aerosol propellent formulations | |
EP0229652B1 (en) | Stabilized tocopherol in dry, particulate, free-flowing form | |
CA1205383A (en) | Method of encapsulating biologically active materials in multilamellar lipid vesicles (mlv) | |
EP0725620B1 (en) | Non-sweating lipsticks | |
US4849132A (en) | Surfactant composition having improved functions | |
CA2062854A1 (en) | Pharmaceutical aerosol formulations | |
JPH024899A (en) | Oxidation inhibitor | |
JPH0753661B2 (en) | Pro-liposome composition and method of making an aqueous dispersion of liposomes | |
JPH06287108A (en) | Anhydrous make-up goods composition containing fat phase and make-up processing method using said composition | |
JPH08500972A (en) | How to remove oil from raw lecithin | |
CA2073096C (en) | Phospholipid composition | |
WO2005077419A1 (en) | Soft capsule preparation | |
EP0242812A1 (en) | Use of glycofurol in liquefying pharmaceutical preparations for filling soft gelatin capsules | |
US6288130B1 (en) | Oil-free glycerophospholipid formulations and method for the production thereof | |
CA2388169A1 (en) | Phospholipid composition and use of same | |
EP1659878A2 (en) | Formulation based on phospholipids | |
JP2005290308A (en) | Method for producing phospholipid composition, and pharmaceutical composition, cosmetic composition or food composition using the same | |
JPH06279467A (en) | Phospholipid composition | |
JP3061777B2 (en) | Egg yolk lecithin mixture | |
EP0950392B1 (en) | Non-sweating lipsticks | |
US4022923A (en) | Frozen garlic and method of producing the same | |
JPH0570793A (en) | Granular lipid composition |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM4A | Patent lapsed |